Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features
Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features
复制标题
DOI：
10.1016/j.lungcan.2019.06.020
复制
发表时间：
2019-09-01
期刊：
影响因子：
5.3
通讯作者：
Madabhushi, Anant
中科院分区：
文献类型：
--
作者：
Khorrami, Mohammadhadi;Jain, Prantesh;Madabhushi, Anant
目的：在IIIA期NSCLC患者中使用新辅助放化疗后手术是有争议的，手术的获益有限。目前没有临床验证的生物标志物来选择用于这种方法的患者。在这项研究中，我们评估了计算机断层扫描（CT）衍生的瘤内和瘤周纹理和结节形状特征预测主要病理反应（MPR）的能力。MPR定义为
Objective: The use of a neoadjuvant chemoradiation followed by surgery in patients with stage IIIA NSCLC is controversial and the benefit of surgery is limited. There are currently no clinically validated biomarkers to select patients for such an approach. In this study we evaluate computed tomography (CT) derived intratumoral and peritumoral texture and nodule shape features in their ability to predict major pathological response (MPR). MPR being defined as